SillaJen's Anticancer Candidate 'BAL0891' Presented in Preclinical Poster at European Conference

BAL0891 Poster Presentation. [Photo by Sillajen]

[Asia Economy Reporter Lee Gwan-ju] SillaJen announced on the 1st that the preclinical results of the anticancer drug candidate 'BAL0891', introduced from Swiss company Vaselia, were presented as a poster at the '2022 EORTC-NCI-AACR' symposium held in Barcelona, Spain.

This symposium is an international conference jointly hosted by the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research, held annually in Europe and the United States.

According to Vaselia, BAL0891 showed high anticancer efficacy as a monotherapy in a triple-negative breast cancer (TNBC) xenograft model, and demonstrated strong synergistic effects in combination therapy with Paclitaxel. In an ovarian cancer cell line xenograft model, it also showed synergistic effects in combination with Carboplatin, suggesting potential expansion to various hard-to-treat cancer types.

BAL0891, a mitotic checkpoint inhibitor (MCI), is a dual kinase inhibitor that inhibits two phosphorylation enzymes, threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). BAL0891 has already received FDA approval for phase 1 clinical trials and is preparing to enroll patients at three sites in the United States.

A SillaJen official stated, "Reviewing the preclinical results of BAL0891, the combination with Paclitaxel showed synergistic anticancer efficacy," adding, "This is meaningful for planning the dose, schedule, and order of combination drugs for the upcoming phase 1 clinical trial, which will target metastatic solid tumors."

This content was produced with the assistance of AI translation services.